Advertisement


Tycel J. Phillips, MD, and Emanuele Zucca, MD, on Primary Mediastinal B-Cell Lymphoma: New Data on Observation vs Radiotherapy

2023 ASCO Annual Meeting

Advertisement

Tycel J. Phillips, MD, of City of Hope National Medical Center, and Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and the International Extranodal Lymphoma Study Group, discuss findings from the largest prospective study of patients with primary mediastinal B-cell lymphoma. The trial data support omitting radiotherapy in patients who achieve complete metabolic response after immunochemotherapy (Abstract LBA7505).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Tycel J. Phillips, MD: What led you guys to investigate whether omission of radiation was possible? Emanuele Zucca, MD: The first issue to keep in mind is that primary mediastinal large cell lymphoma is a totally separate and particular entity which is affecting younger people in their 30 and 40 years of age, mainly white women but not just them, and is presenting with a bulky chest mass. And at the end of induction immunochemotherapy, nearly all the patient still have a residual lesion in the chest. And the fact that patient with earlier relapse or not rapid remission had this malprognosis led many investigative doctors to give to everybody consolidation radiotherapy to the mediastinal after induction immunochemotherapy. And this is increasing the risk of second cancer and delayed cardiac toxicity, both valvular and ischemic cardiac disease. This was the first part of the story. Second part is that roughly 15, 20 years ago at the NIH has been developed a regimen called dose-adjusted EPOCH-R, which was quite promising in this disease. And there were data indicating that perhaps radiotherapy was no longer needed for patients responding to immunochemotherapy. This led actually to a never-ending controversy and there are people and many countries where radiotherapy has remained in the standard, for example, in Italy or in Germany, and others, for example, just to stay in Europe, in France where radiotherapy was no longer used. And- Tycel J. Phillips, MD: That's a very good- Emanuele Zucca, MD: ... and this prompted us to design a study to address this controversy. Tycel J. Phillips, MD: No, no, that's a very, very good point. I mean, because I think as you pointed out with dose-adjusted EPOCH, I think a lot of us US investigators prefer that regimen over the ability to hopefully omit radiation, whereas we almost felt obligated with R-CHOP, so I think your study will add a lot of context to that controversy. Emanuele Zucca, MD: Yes. First, our study has a byproduct to show that standard R-CHOP given every three weeks is likely inferior to the more aggressive dose-enhanced regimens including EPOCH-R. But the main result of the study is that we can actually spare radiotherapy to the people achieving a metabolic complete response after immunochemotherapy. Tycel J. Phillips, MD: And that's any immunochemotherapy, correct? Emanuele Zucca, MD: Yes. Tycel J. Phillips, MD: Okay. Emanuele Zucca, MD: The point is that they have with PET scan a residual uptake in the residual lesions which has to be below the liver uptake. This is called Deauville score 3 and is indicating a complete metabolic response as well as lower uptakes, which are Deauville score of 1 or 2. And patients achieving a metabolic response on PET scan do not need radiotherapy according to our results. There is a very tiny benefit of radiotherapy, around at 2%, which is not translating in any superiority of overall survival. Patients achieving a complete remission at three years after study entry had 99% survival rates irrespectively of whether they got or not radiotherapy. Tycel J. Phillips, MD: That's excellent. So I think as you pointed out very clearly, it's very important to know that even if the patients actually got R-CHOP and went into remission, that you could safely omit radiotherapy if they were PET negative. Emanuele Zucca, MD: Yes. Tycel J. Phillips, MD: So what are the next steps for this study as it matures? Emanuele Zucca, MD: Which was somehow surprising us during the study was that we had a very low rate of events. However, the rate of complete remission by PET at the end of immunochemotherapy was only about 50%. So I am expecting that there is a portion of patients with partial remission in this PET scan evaluation who are actually with no longer active tumor, but just is a problem of very high sensitivity of modern PET scans. And for this reason, we will investigate whether we can use liquid biopsy to see whether a partial response is in need of additional radiotherapy or not. That is what we are discussing for the future. Tycel J. Phillips, MD: No, that would be actually a phenomenal study to do, because I think we've all seen areas with partial responses, especially with PET scans and areas that we can't reach and sort of question whether that's actually true responses, so to be able correlate that with liquid biopsies would be a monumental step forward for all of us to better understand these diseases. I think overall, I mean I think this contribution of this abstract is very helpful for, as you already mentioned, a very young patient population. One last question before we wrap up. As far as the side effect profile, have you guys noticed anything in the short term in the group that was randomized to radiation versus those that did not get radiation? Emanuele Zucca, MD: There is no data indicating that there is a subset of patients who are likely experiencing a different outcome. I think that the study has a very simple take-home message, which is no radiotherapy for those in complete remission, and also, thus far it is too early for addressing delayed toxicity, but [inaudible 00:06:49] we had six serious events with three serious cardiac events and three second cancers, all of them in the radiation therapy arm. Tycel J. Phillips, MD: Interesting. Emanuele Zucca, MD: Which is supporting even more the study results. Tycel J. Phillips, MD: No, I agree. Thank you. Great study, great presentation. And I look forward to further maturation of the study data. I'm assuming we all do and I appreciate you taking the time to talk to me this afternoon. Emanuele Zucca, MD: It was nice to meet you. Tycel J. Phillips, MD: Yeah, thank you. Emanuele Zucca, MD: Bye.

Related Videos

Lung Cancer
Immunotherapy

Jonathan W. Riess, MD, on EGFR-Mutated Non–Small Cell Lung Cancer: What’s Next?

Jonathan W. Riess, MD, of the University of California, Davis Comprehensive Cancer Center, explores the findings of three important clinical trials in lung cancer treatment: whether to incorporate immune checkpoint inhibitors into the treatment of EGFR-mutated lung cancer, the importance of central nervous system activity in EGFR-mutant lung cancer, and new therapies for disease with EGFR exon 20 insertion.

Leukemia

Claire Roddie, PhD, MBChB, on B-ALL: Safety and Efficacy Data of Obecabtagene Autoleucel

Claire Roddie, PhD, MBChB, of University College London, discusses results of the FELIX study, which showed that the second-generation chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel is safe for adults with relapsed or refractory B-cell acute lymphoblastic leukemia, even those with a high burden of disease. This agent yielded high rates of complete response and ongoing CAR T-cell persistence in most patients whose disease responded (Abstract 7000).

Lung Cancer

Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib

Nagla Abdel Karim, MD, of the Inova Schar Cancer Institute, University of Virginia, discusses phase II data showing that maintenance atezolizumab plus talazoparib improved progression-free survival in Schlafen-11–selected patients with extensive-stage small cell lung cancer. This study demonstrated the feasibility of conducting biomarker-selected trials in this disease, paving the way for future evaluation of novel therapies in selected populations (Abstract 8504).

Lymphoma

Catherine C. Coombs, MD, on B-Cell Malignancies and Long-Term Safety of Pirtobrutinib

Catherine C. Coombs, MD, of the University of California, Irvine, discusses prolonged pirtobrutinib therapy, which continues to demonstrate a safety profile amenable to long-term administration at the recommended dose without evidence of new or worsening toxicity signals. The safety and tolerability observed in patients on therapy for 12 months or more were similar to previously published safety analyses of all patients enrolled, regardless of follow-up (Abstract 7513).

Leukemia

Eunice S. Wang, MD, and Gregory Roloff, MD, on B-ALL: Outcomes With Brexucabtagene Autoleucel in Adult Patients

Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, and Gregory Roloff, MD, of the University of Chicago, discuss data that are the first to demonstrate post–FDA approval efficacy and toxicity rates of brexucabtagene autoleucel in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Although the data may confirm high response rates associated with this agent, they also highlight the need for interventions to reduce associated toxicities (Abstract 7001).

Advertisement

Advertisement




Advertisement